![]() |
| Das Dokument ist frei verfügbar |
|
| | Nachweis | Kein Nachweis verfügbar |
|
| In this Statement EASAC builds on a long-standing interest in the opportunities and challenges associated with tackling infectious diseases to re-examine the current situation to consider how to search for new scientific directions for antimicrobial innovation and to remove impediments in translating research advances to drug development. In March 2014 EASAC together with its member academies in Germany and the Netherlands organised a meeting in Hannover to explore new paths in antibiotic research. Among key topics elucidated and exemplified were the following: How can we learn from previous examples of success and lack of success in antibiotic research and development? - What are the functions of antibiotics in their natural environments? - What are the opportunities for novel approaches to tackling pathogens for example based on virulence modulation or immune stimulation? - How might pathogen-specific pathways be influenced? - Can host cell targets be found that inhibit intracellular bacterial infection? - Are there new sources of antimicrobial compounds and delivery systems that can capitalise on emerging technologies? / There was consensus among the participants at the meeting on the urgency to develop critical mass to support and generate good new science to dismantle the bureaucratic obstacles to using the outputs from that science and to ensure that innovation can be sustained in the longer term. The Statement concludes that much needs to be done to enhance antibiotic innovation: to define and validate better targets to ensure high-quality clinical research facilities to streamline regulation and to tackle the market problems so that companies are attracted back into the therapeutic area. |
|
|